Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Device Prices Plunge as Hospitals Pay Less to Fix Hearts
Bloomberg
Monday, September 23, 2013 - 9:54am
tags:
devices, drug eluting stents, medical device tax
Acceleron: A Small Biotech Preparing To Supply Big Markets
Seeking Alpha
Monday, September 23, 2013 - 9:47am
tags:
Acceleron, Amgen, Celgene, IPOs
NanoString: An Exciting Small Cap Story With A Strong Growth Outlook
Seeking Alpha
Monday, September 23, 2013 - 9:41am
tags:
NanoString Technologies
Alexion reports data from Phase 2 study of asfotase alfa
Yahoo/Fly on the Wall
Monday, September 23, 2013 - 9:39am
tags:
Alexion, asfotase alfa, hypophosphatasia
Five Prime Therapeutics - Another Risky Cancer Research Public Offering
Seeking Alpha
Monday, September 23, 2013 - 9:38am
tags:
Five Prime, IPOs, cancer
CHMP thumbs up for 11 new drugs
Pharma Times, UK
Monday, September 23, 2013 - 9:33am
tags:
Europe, drug approvals, Kadcyla, Roche, Bayer, Xofigo, Abilify Maintena, Otsuka, Lundbeck, Memantine Accord, Accord Healthcare, Levodopa Carbidopa Entacapone Sandoz, Orion, Vitekta, Gilead, Janssen-Cilag, Invokana, Novo Nordisk, NovoEight, AstraZeneca, Fluenz Tetra, GSK, Relvar Ellipta, Lidocaine/Prilocaine Plethora, Plethora Solutions
Novartis board member suggests Roche merger
Independent.ie, Ireland
Monday, September 23, 2013 - 9:25am
tags:
Novartis, M&A, Roche
Under Sedation? A Merck Setback As FDA Rejects Anesthesia Drug
Pharmalot
Monday, September 23, 2013 - 9:22am
tags:
Merck, anesthesia, FDA, Bridon, sugammadex
Cardiome publishes positive data from vernakalant, propafenone comparative study
Yahoo/Fly on the Wall
Monday, September 23, 2013 - 9:20am
tags:
Cardiome, Vernakalant, propafenone, atrial fibrillation
On health-care fraud, US is pennywise, poundfoolish
CNBC
Monday, September 23, 2013 - 9:18am
tags:
healthcare fraud
Ablynx Rises on Drug Licensing Deal With AbbVie
Bloomberg
Monday, September 23, 2013 - 9:17am
tags:
Ablynx, AbbVie, ALX-0061, rheumatoid arthritis
Should You Buy Protalix for Its Platform Alone?
Motley Fool
Sunday, September 22, 2013 - 11:37am
tags:
Protalix BioTherapeutics, ProCellEx
Acceleron Pharma - Successful Cancer Research IPO
Seeking Alpha
Sunday, September 22, 2013 - 11:35am
tags:
Acceleron
Cytori Therapeutics - Independent Study On Scleroderma Shows Great Results
Seeking Alpha
Sunday, September 22, 2013 - 11:34am
tags:
Cytori, scleroderma
BioMarin's Buyout False Start Leads Biotech's Record Surge
Motley Fool
Sunday, September 22, 2013 - 11:32am
tags:
Biomarin, Roche
Is this Cancer-Fighting Biotech for Sale?
Motley Fool
Sunday, September 22, 2013 - 11:31am
tags:
Clovis Oncology
China Biotech In Review: Novartis Has A Novel Scandal Potentially Brewing
Seeking Alpha
Sunday, September 22, 2013 - 11:27am
tags:
CanSino Biotech, Huahai Pharma, Boston Scientific, Novartis, Alcon
Groundbreaking Diabetes Drug Headlines Approval Bonanza
Motley Fool
Sunday, September 22, 2013 - 11:25am
tags:
diabetes, type 2 diabetes, type 1 diabetes, JNJ, inokana, Forxiga, AstraZeneca, Bristol-Myers Squibb
5 Experimental Drugs That Could Make a Big Difference in Treating Lung Cancer
Motley Fool
Sunday, September 22, 2013 - 11:23am
tags:
LDK378, Novartis, bavituximab, Peregrine Pharmaceuticals, nivolumab, Bristol-Myers Squibb, lambrolizumab, Merck, lung cancer, CO-1686, Clovis Oncology
3 Drugmakers Developing Revolutionary Psoriasis Treatments
Motley Fool
Sunday, September 22, 2013 - 11:20am
tags:
Celgene, Novartis, Eli Lilly

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.